R1 RCM's (RCM) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of R1 RCM (NASDAQ:RCM - Free Report) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $20.00 target price on the healthcare provider's stock.

Other equities analysts have also issued research reports about the stock. Evercore ISI reiterated an in-line rating and set a $16.00 price objective (up previously from $12.00) on shares of R1 RCM in a report on Wednesday, February 28th. Leerink Partnrs reaffirmed an outperform rating on shares of R1 RCM in a research note on Monday, February 26th. Barclays reissued an equal weight rating and issued a $14.00 price objective on shares of R1 RCM in a research note on Wednesday, February 28th. SVB Leerink started coverage on R1 RCM in a report on Monday, February 26th. They set an outperform rating and a $14.00 price objective for the company. Finally, Guggenheim cut their target price on R1 RCM from $17.00 to $15.00 and set a buy rating on the stock in a report on Friday, April 5th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $17.00.

R1 RCM Price Performance

Shares of NASDAQ:RCM traded down $0.17 during mid-day trading on Wednesday, hitting $12.70. The company had a trading volume of 1,785,711 shares, compared to its average volume of 3,949,926. R1 RCM has a one year low of $8.87 and a one year high of $18.70. The firm has a fifty day moving average price of $12.49 and a 200 day moving average price of $11.65. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.83 and a current ratio of 1.83.

Insiders Place Their Bets

In related news, President John M. Sparby sold 10,046 shares of R1 RCM stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the sale, the president now owns 265,986 shares of the company's stock, valued at approximately $3,811,579.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 37.00% of the company's stock.

Institutional Investors Weigh In On R1 RCM

Several large investors have recently added to or reduced their stakes in the company. Point72 Middle East FZE purchased a new position in R1 RCM in the 4th quarter valued at approximately $29,000. Captrust Financial Advisors grew its position in shares of R1 RCM by 81.7% in the second quarter. Captrust Financial Advisors now owns 1,664 shares of the healthcare provider's stock valued at $35,000 after purchasing an additional 748 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of R1 RCM in the third quarter valued at $36,000. ANTIPODES PARTNERS Ltd raised its stake in shares of R1 RCM by 429.5% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider's stock valued at $59,000 after purchasing an additional 4,561 shares during the period. Finally, Salem Investment Counselors Inc. purchased a new stake in R1 RCM during the 4th quarter worth about $61,000. Hedge funds and other institutional investors own 61.10% of the company's stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.